Hangzhou Tigermed Consulting Co., Ltd.
HNGZY
Price:
$4
Market Cap:
$36.49B
Hangzhou Tigermed Consulting Co., Ltd. provides contract research organization services in the People's Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The company offers regulatory submission and approval, medical translation, and good manufacturing practice (GMP) consulting services; and clinical services in the areas of medical science, early clinical and late phase development, medical monitoring, project management, patient recruitment, and quality management system. It also provides biometrics services comprising data management, biostatistics, and statistical programming; and integrated technology s...[Read more]
Industry
Medical - Diagnostics & Research
IPO Date
2022-07-11
Stock Exchange
OTC
Ticker
HNGZY
PE Ratio
[26.67]
ROE
[2.95%]
Current Ratio
[2.16]
Dividend Yield
[0.61%]
Enterprise Value
[36.59B]
Dividend History
The ROE as of December 2025 (TTM) for Hangzhou Tigermed Consulting Co., Ltd. (HNGZY) is 2.95%
According to Hangzhou Tigermed Consulting Co., Ltd.’s latest financial reports and current stock price. The company's current ROE is 2.95%. This represents a change of 307.28% compared to the average of 0.73% of the last 4 quarters.
Hangzhou Tigermed Consulting Co., Ltd. (HNGZY) Historical ROE (quarterly & annually)
How has HNGZY ROE performed in the past?
The mean historical ROE of Hangzhou Tigermed Consulting Co., Ltd. over the last ten years is 12.24%. The current 2.95% ROE has changed -75.87% with respect to the historical average. Over the past ten years (40 quarters), HNGZY's ROE was at its highest in in the June 2020 quarter at 14.34%. The ROE was at its lowest in in the December 2024 quarter at -1.98%.
Average
12.24%
Median
11.44%
Minimum
1.96%
Maximum
19.92%
Hangzhou Tigermed Consulting Co., Ltd. (HNGZY) ROE by Quarter and Year
Discovering the peaks and valleys of Hangzhou Tigermed Consulting Co., Ltd. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 47.16%
Maximum Annual ROE = 19.92%
Minimum Annual Increase = -79.65%
Minimum Annual ROE = 1.96%
| Year | ROE | Change |
|---|---|---|
| 2024 | 1.96% | -79.65% |
| 2023 | 9.63% | -6.02% |
| 2022 | 10.25% | -35.39% |
| 2021 | 15.86% | 46.09% |
| 2020 | 10.86% | -45.50% |
| 2019 | 19.92% | 12.57% |
| 2018 | 17.69% | 47.16% |
| 2017 | 12.02% | 39.07% |
| 2016 | 8.65% | -44.55% |
| 2015 | 15.59% | 7.28% |
Hangzhou Tigermed Consulting Co., Ltd. (HNGZY) Average ROE
How has HNGZY ROE performed in the past?
The current ROE of Hangzhou Tigermed Consulting Co., Ltd. (HNGZY) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
7.28%
5-year avg
9.71%
10-year avg
12.24%
Hangzhou Tigermed Consulting Co., Ltd. (HNGZY) ROE vs. Peers
How is HNGZY’s ROE compared to its peers?
Hangzhou Tigermed Consulting Co., Ltd.’s ROE is greater than McKesson Europe AG (-2.26%), greater than Dechra Pharmaceuticals PLC (-3.92%), greater than Dechra Pharmaceuticals PLC (-3.92%), less than Mediclinic International plc (5.07%), less than Sugi Holdings Co.,Ltd. (16.20%), less than Galenica AG (12.86%), less than Abcam plc (0.76%), less than IHH Healthcare Berhad (7.45%), less than Takara Bio Inc. (0.52%), less than Ipsen S.A. (10.65%),
| Company | ROE | Market cap |
|---|---|---|
| -2.26% | $5.37B | |
| -3.92% | $5.34B | |
| -3.92% | $5.58B | |
| 5.07% | $4.05B | |
| 16.20% | $2.95B | |
| 12.86% | $5.23B | |
| 0.76% | $5.12B | |
| 7.45% | $12.81B | |
| 0.52% | $2.79B | |
| 10.65% | $9.35B |
Build a custom stock screener for Hangzhou Tigermed Consulting Co., Ltd. (HNGZY) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Hangzhou Tigermed Consulting Co., Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Hangzhou Tigermed Consulting Co., Ltd. (HNGZY) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Hangzhou Tigermed Consulting Co., Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Hangzhou Tigermed Consulting Co., Ltd.'s ROE?
How is the ROE calculated for Hangzhou Tigermed Consulting Co., Ltd. (HNGZY)?
What is the highest ROE for Hangzhou Tigermed Consulting Co., Ltd. (HNGZY)?
What is the 3-year average ROE for Hangzhou Tigermed Consulting Co., Ltd. (HNGZY)?
What is the 5-year average ROE for Hangzhou Tigermed Consulting Co., Ltd. (HNGZY)?
How does the current ROE for Hangzhou Tigermed Consulting Co., Ltd. (HNGZY) compare to its historical average?